DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.
View Top Employees from DBV TechnologiesWebsite | http://www.dbv-technologies.com |
Ticker | DBVT |
Revenue | $5.3 million |
Funding | $471.4 million |
Employees | 183 (175 on RocketReach) |
Founded | 2002 |
Address | 177-181 Ave Pierre Brossolette, Montrouge, Ile-de-France 92120, FR |
Phone | +33 1 55 42 78 78 |
Fax | +33 1 43 26 10 83 |
Technologies |
JavaScript,
HTML,
PHP
+44 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Allergy, Pharmaceuticals, Science and Engineering, Food and pediatric allergy, Healthcare, Health Care, Specific immunotherapy, Health Diagnostics, Epicutaneous Delivery Device |
Web Rank | 2 Million |
Keywords | Allergy Treatment |
Competitors | Altea Therapeutics, Apellis Pharmaceuticals, Jounce Therapeutics, Inc., Kite Pharma, Sorrento Therapeutics, Inc. |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular DBV Technologies employee's phone or email?
The DBV Technologies annual revenue was $5.3 million in 2024.
Sebastien ROBITAILLE is the CFO of DBV Technologies.
175 people are employed at DBV Technologies.
DBV Technologies is based in Montrouge, Ile-de-France.
The NAICS codes for DBV Technologies are [54171, 54, 541714, 541, 5417].
The SIC codes for DBV Technologies are [87, 873].